�
Kidney cancer known as renal cell cancer, originated in the renal tubular epithelial cells, is the most common kidney cancer, kidney cancer accounts for about 75% of the total number to 80%, age of onset in 40 to 60 years. About 20.8 million people worldwide each year are diagnosed with the kidney, 10.2 million people died of kidney cancer. In China, the kidney cancer incidence rate was 27.8%, the mortality rate was 40%, second only to urinary bladder cancer is the second largest killer.
Early asymptomatic renal cell carcinoma, mostly sudden hematuria, because there is no pain or any discomfort, easily overlooked; to the middle and late to frequent hematuria, abdominal mass and pain-based disease, also can be accompanied by fever, anemia, fatigue, weight loss and other symptoms; With the further deterioration of the transfer of advanced lung cough, hemoptysis; transfer of bone pain, fractures; brain metastasis, headache, hemiplegia, etc., occasionally varicocele, polycythemia , hypercalcemia, amyloidosis and non-metastatic liver failure.
Past treatment of renal cell carcinoma based primarily radical surgery, that is, the side of the kidney in patients with total removal of the tumor to eradicate hidden dangers. However, the ensuing question is: As patients decreased effective renal unit, once the other side of the kidney disease also will bring a fatal blow. menshealthknowledge.com
Large number of clinical practice shows that, for advanced kidney cancer patients high-dose chemotherapy and radiotherapy, or in patients resistant to chemotherapy again, can only lead to weakness of life more dying, accelerated death. Clinical often can be seen, not because of patient death caused by cancer itself, but because of the unscientific, inappropriate treatment due to the destruction. Repeated intervention such as liver, ascites, jaundice and other liver failure and death; lung cancer after chemotherapy, pleural effusion leading to respiratory failure and death; gastric cancer, colon cancer chemotherapy nausea and vomiting, the body is more failure and death; decreased white blood cells, patients with infection death.
From: http://menshealthknowledge.com
Therefore, oncologists concerned about the treatment of kidney cancer at the same time, pay more attention to kidney cancer patients survival and quality of life, with survival or even long-term survival with kidney cancer and other cancers has become the treatment of a major research direction. According to the forefront of our field of cancer treatment institutions - the Second Hospital of Beijing Armed Police tumor biological treatment center experts, the center from the United States since 2009, CLS immune therapy, it has been more than 1,000 admissions in patients with advanced cancer. Of these, some lesions appear after the transfer, diffusion, of life full of despair; some are suffering from chemotherapy and radiotherapy the pain and look forward to more advanced treatment. CLS therapy extended survival time for them to improve the quality of life, and the United States and Europe reached a simultaneous treatment. From: http://menshealthknowledge.com
U.S. CLS therapy: anti-tumor therapy fourth Daxin Technology menshealthknowledge.com
How these immune cells and the root causes of cancer to start, to prevent the spread of cancer and metastasis and improve survival in patients with advanced, scientists around the world has been the direction of the treatment of cancer, but also the fundamental way to cancer treatment. In 2008, the United States Temple University, Robert A Weinberg, Ph.D., and Stanford University, Dr. Dietmar W Siemann together cancer scientists in the field, from the rapid development of cytology and immunology to find a breakthrough, developed CLS autologous cell therapy.
They found in the body's immune system, there are two special cells to fight against the cancer cell function: a dendritic cell is like a "radar" that can take the initiative to search for, identify cancer cells; with cells induced killer cell function as "missiles" that can accurately kill tumor cells, without any damage to normal tissue, to effectively kill the tumor but also to enhance the body's immune system. However, the body's normal levels of these two little cells, CLS technology breakthrough is the tremendous success isolated from human peripheral blood cells both by experiment and specialized value-added and activated GMP training, and then reinfusion to the patient body. menshealthknowledge.com
U.S. CLS therapy: 5-year survival rate of increase nearly double
In the medical profession, the cure rate of cancer there is a crucial indicator called the five-year survival rate refers to the after treatment, another five-year period found no clinically visible metastases, tumor lesions, it is considered clinical cure. CLS therapy into clinical treatment in the United States, the well-known cancer specialist, Dr. Yamazaki did a group on the treatment and traditional treatment CLS comparisons. Studies have shown that: use of U.S. cancer patients treatment CLS 3-year survival rate was 72%, 33% unused; 5-year survival rate was 67%, 22% unused. Have made another person happy results.
